DutyPills.com
Women's Sexual Health

Provera in Switzerland: prescription, pharmacy and pricing

Provera (Medroxyprogesterone Acetate) is available in Switzerland under the regulatory framework of Swissmedic (Swiss Agency for Therapeutic Products). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Provera 2.5mg, 5mg, 10mg.

Provera (Medroxyprogesterone Acetate) 2.5mg tablet
Regulator
Swissmedic (Swiss Agency for Therapeutic Products)
Currency
CHF
Active ingredients
Medroxyprogesterone
Available dosages
2.5mg, 5mg, 10mg

Prescription status in Switzerland

Switzerland classifies medicines into categories A and B (prescription-only), C (sold under pharmacist supervision), D (over-the-counter at pharmacies and Drogerien) and E (general retail). Health insurance (Krankenversicherung) covers most prescription costs subject to a deductible (Franchise) and co-payment. Provera contains the active ingredient Medroxyprogesterone, in the Women's Sexual Health class, and its classification in Switzerland follows the standard rules of Swissmedic (Swiss Agency for Therapeutic Products).

Pharmacy dispensing

Swiss Apotheken/pharmacies are densely distributed with strict licensing; pharmacist counselling is integral to dispensing. Drogerien (drugstores) are unique to the Swiss system and sell category D and E medications without a pharmacist on staff. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Provera at the available strengths (2.5mg, 5mg, 10mg).

Online and tele-prescribing access

Swiss online prescription dispensing is regulated by cantonal law, with Swissmedic-licensed services offering tele-prescribing. Cross-border importation for personal use is restricted to small quantities and excludes some controlled substances. Buying Provera from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Medroxyprogesterone.

When Provera is prescribed

Provera is approved for amenorrhoea, abnormal uterine bleeding due to hormonal imbalance, and prevention of endometrial hyperplasia in postmenopausal women receiving estrogen.

Pricing and availability in CHF

Retail pricing in Switzerland depends on the strength (2.5mg, 5mg, 10mg), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.

Frequently asked questions

Do I need a prescription for Provera in Switzerland?

Switzerland classifies medicines into categories A and B (prescription-only), C (sold under pharmacist supervision), D (over-the-counter at pharmacies and Drogerien) and E (general retail). Health insurance (Krankenversicherung) covers most prescription costs subject to a deductible (Franchise) and co-payment. In practice, Provera follows the status of its active ingredient Medroxyprogesterone in the regulatory system of Swissmedic (Swiss Agency for Therapeutic Products).

Is generic Provera available in Switzerland?

Authorised generics of Medroxyprogesterone are typically available in Switzerland at a lower cost than branded Provera, with bioequivalence required by Swissmedic (Swiss Agency for Therapeutic Products). Substitution is handled by the pharmacist under local equivalence rules.

How much does Provera cost in CHF?

Prices in CHF vary by pharmacy and by strength (2.5mg, 5mg, 10mg). Authorised generics of Medroxyprogesterone are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Switzerland.

Provera in other countries

The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.